ChromoCure, Inc. Issues Stockholder Update

RENO, NV, Jul 30 (MARKET WIRE) --
ChromoCure, Inc. (PINKSHEETS: KKUR) issued a stockholder update on the
progress of its initial disclosure statements, financial reporting, and
business plan execution.

Financial Reporting and Regular Disclosures

The Company is completing its full disclosure statement published pursuant
to paragraphs (a)(5)(i) to (xiv), inclusive, and paragraph (a)(5)(xvi) of
Rule 240.15c2-11 and the OTC Disclosure Guidelines. The information filed
will be substantially equivalent to the SEC's "Form 10" document. The
Company anticipates filing its complete disclosures on 10 August 2009.

Revenue Projections and Industry/Sector Analysis

The Company will make public several aspects of its business plan and its
technology. These announcements will contain analyses of specific sectors
of the cancer diagnostic industry. Contained within these market surveys
and analyses will be revenue estimates and projections. The public release
of information will begin on 4 August 2009 and simultaneously filed with
the OTC Disclosure Service.

Investors timely updated on the following:

-- Elimination of all long-term liabilities and removal from the Balance
Sheet.
-- Acquisition of intellectual property, technology, and subsequent
patent filings
-- Additional appointment to the Company's Advisory and Business
Development Boards.
-- Acquisition of profitable pathology labs to expand the company's
operations
-- Research and Development agreements with industry partners
-- Regular updates and commentary on the Company's proprietary technology
and development.
-- Revenue estimates by industry sector

About ChromoCure

ChromoCure develops and provides proprietary cancer detection systems. The
Company owns its technology and provides its systems on a revenue sharing
basis. The Company's systems measure the unique genomic characteristic
common to all cancers and never found in normal cells. The Company
believes its technology has an effective accuracy of 100% for all cancers
at all stages. The Company believes its technology vastly superior to
anything in existence and that it will become the undisputed gold standard
for cancer detection worldwide.

The Company's technology and understanding of cancer also suggest
non-toxic and non-invasive approaches to cancer therapy and cure
research. The Company will release progress reports on these initiatives
from time to time.

Safe-Harbor Statement

This press release contains statements (such as projections regarding
future performance) that are forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995. Actual results may
differ materially from those projected as a result of certain risks and
uncertainties. The company's website version of this press release
contains various RISK FACTORS (and are incorporated herein by reference)
and should be read before any investment decision.

Investor Relations:
Contact:
ChromoCure, Inc.
info@chromocure.com
Tel 1.775.636.6548

Copyright 2009, Market Wire, All rights reserved.

-0-